Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma

Table 5 Adverse events n (%)

Adverse effect	Treatment group (%)		P value
	DDPH group (n = 76)	ADM group (n = 88)
Nausea/vomiting	64 (84)	48 (55)	< 0.001
Fever	61 (80)	73 (83)	0.571
Abdominal pain	53 (69)	63 (72)	0.958
Elevation of transaminase levels	55 (72)	62 (71)	0.993
Liver abscess	1 (1)	2 (2)	0.765
Hepatic arterial damage	1 (1)	16 (18)	< 0.001
Renal or liver failure	0 (0)	2 (2)	0.229
Leucopenia	3 (4)	12 (14)	0.002
Thrombocytopenia	4 (5)	6 (7)	0.650
Fatigue	21(28)	27 (31)	0.839

DDPH group: Using a suspension of DDPH in lipiodol (LPD); ADM group: With an emulsion of doxorubicin (ADM) with LPD; Data are expressed as number of patients, with the percentages indicated in parentheses.